about
Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers.Prevalence of metabolic syndrome components in an urban Mexican sample: comparison between two classificationsEffect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistanceAdipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy.Postprandial insulin resistance as an early predictor of cardiovascular risk.New developments in the management of congenital Factor XIII deficiency.Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseasesElevated heparin-induced antibodies are more common in diabetic patients with vascular disease.New developments in the area of factor XIII.Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.Proteomic characteristics of circulating microparticles in patients with newly-diagnosed type 2 diabetes.Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?Platelet aggregation is not enhanced in patients with prediabetes.Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.Hypoglycaemia, thrombosis and vascular events in diabetes.
P2860
Q35142660-D9AF8DEE-ACBE-4CD2-9A1D-9AAD820C2F64Q35607305-CD97E1CF-693A-4445-801E-4F50D793BBB8Q36397303-CAB8CF98-E4D2-4BC9-A6C7-63504D174BB5Q36502941-EFEBD563-0C63-4A47-80B5-5CFFFC6BC248Q36645776-AB664D21-B1D7-42B0-B4A7-D76CB2896F24Q36906072-5B743BDC-6ABC-495B-99C2-23FB0F01C5DEQ37017506-380C3192-D45E-4449-AAD5-704CC8D5E76BQ37615123-F4D3162D-B51D-4B44-9604-4D0CFB5B1938Q38070913-BF5A64E9-6DDB-4DE6-9CDD-E47C3724B6F6Q38077284-22A36438-98D1-4D1A-B74A-76F1B3517A38Q38448646-EB6C3C63-4539-4492-93B7-CAA49B58747DQ42855410-668A22E9-15E2-4753-986F-C9BF6DB228CCQ43724690-C0CEAB44-524A-406D-9985-5F186E4326F4Q51298130-26819A19-3752-4AEB-8350-8C7E8EE9DBABQ51630897-9E5AB7EE-7127-4B48-AB51-FC8F3B485AAFQ52815156-48B1A176-6415-47F4-BB76-C16330CC6B5B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Type 2 diabetes: an atherothrombotic syndrome.
@ast
Type 2 diabetes: an atherothrombotic syndrome.
@en
type
label
Type 2 diabetes: an atherothrombotic syndrome.
@ast
Type 2 diabetes: an atherothrombotic syndrome.
@en
prefLabel
Type 2 diabetes: an atherothrombotic syndrome.
@ast
Type 2 diabetes: an atherothrombotic syndrome.
@en
P356
P1476
Type 2 diabetes: an atherothrombotic syndrome.
@en
P2093
P304
P356
10.2174/1566524053766059
P577
2005-05-01T00:00:00Z